Journal of Ophthalmology / 2014 / Article / Tab 1

Clinical Study

Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma

Table 1

Clinical profile of 26 eyes of 25 cases from the Collaborative Choroidal Osteoma Group .

Case .AgeGenderOsteoma
location
CNV locationInitial
vision
Final visionInitial CFT6-month CFTType of injectionsFollow-up (month)Number of injectionOsteoma longest dimension (disc diameter)

134FSubfovealJuxtafoveal20/300 (6/90)20/60 (6/18)NA174Bevacizumab1823

237MPosterior poleSubfoveal with blood20/25 (6/7.5)20/20 (6/6)NANABevacizumab52810

343FSubfovealSubfoveal with blood20/32 (6/9.5)20/100 (6/30)294197Ranibizumab1814

48FSubfovealSubfoveal with bloodCF20/40 (6/12)434NABevacizumab2427

528MSubfovealSubfoveal with SRF20/60 (6/18)20/80 (6/24)373252Bevacizumab4637

613FSubfovealSubfoveal with blood20/100 (6/30)20/50 (6/15)307212Ranibizumab4235

727MSuperotemporal arcadeExtrafoveal with blood20/80 (6/24)20/30 (6/9)NANARanibizumab1879

827FSubfovealExtrafoveal20/30 (6/9)20/20 (6/6)264207Bevacizumab1214

946FSubfovealSubfoveal with blood20/300 (6/90)20/80 (6/24)244NABevacizumab6086

1037FPosterior polePeripapillary20/80 (6/24)20/20 (6/6)790360Bevacizumab2641

1128FPosterior polePeripapillary20/400 (6/120)20/400 (6/120)Highly elevated serous macular detachmenthighly elevated serous macular detachmentRanibizumab824

1248FSubfoveal & juxtafovealSubfoveal & juxtafoveal20/40 (6/12)20/20 (6/6)298306Ranibizumab number 5, Bevacizumab number 1035153

1325FSubfovealSubfoveal20/80 (6/24)20/20 (6/6)203166Ranibizumab1511

1433FSubfovealSubfoveal(20/67) 6/20(20/320) 6/95316Bevacizumab2432

1522MSubfovealJuxtafovealCF 1 mCF 2 mNA675Bevacizumab736

1641FJuxtafovealJuxtafoveal20/200 (6/60)20/200 (6/60)427258Ranibizumab number 3 Bevacizumab number 1643

1724MExtrafovealExtrafoveal with blood20/60 (6/18)20/30 (6/9)350210Bevacizumab54172

1814MSubfovealSubfoveal with bloodCFNFCFNF>1000>500Bevacizumab number 4 Ranibizumab number 52698

1935FPosterior polePeripapillary20/70 (6/21)20/40 (6/12)600400Bevacizumab1227

2045MSubfovealJuxtafoveal20/63 (6/19)20/32 (6/9.5)237222Bevacizumab621.2

2113FSubfovealSubfoveal20/200 (6/60)20/63 (6/19)339249Bevacizumab624

2220MSubfovealJuxtafoveal20/70 (6/21)20/40 (6/12)282171Bevacizumab7114

2322MSubfovealSubfoveal20/160 (6/48)20/250 (6/75)427225Bevacizumab4654.9

2411MJuxtafovealExtrafoveal20/20 (6/6)20/20 (6/6)NANABevacizumab1633.4

2557FSubfovealSubfoveal20/800 (6/240)20/30 (6/9)NA283Ranibizumab number 3 Bevacizumab number 32164

2625FExtrafovealSubfoveal20/300 (6/90)20/100 (6/30)360320Bevacizumab1226

= number; CFT = central foveal thickness; SRF = subretinal fluid; F = female; M = male; NA = not available; CF = counting fingers; CFNF = finger counting at near face.